Paliperidone, Serum or Plasma
2007949
 
Ordering Recommendation
Therapeutic monitoring of paliperidone (eg, Invega).
Mnemonic
PALIPERID
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun, Wed
Reported
1-5 days
N/A
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Pre-dose (trough) draw - At steady state concentration.  
Collect
Lavender (EDTA), pink (K2EDTA) or plain red.  
Specimen Preparation
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).  
Remarks
N/A  
Stability
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months  
Reference Interval
Therapeutic range: Not well established
Proposed Dose-​Related Range: Paliperidone (9-​hydroxyrisperidone): 20 -​ 60 ng/mL
Toxic range: Not well established
Interpretive Data
Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
80299
Components
Component Test Code*Component Chart Name
2007950Paliperidone, Serum/Plasma
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • 9-hydroxyrisperidone
  • Invega
  • invega blood level